中国浙江杭州，2025年4月22日，浙江道尔生物科技有限公司（"道尔生物"），一家针对代谢性疾病和癌症开发创新生物治疗药物的临床阶段的生物制药公司，今日宣布其自主研发的靶向成纤维细胞生长因子21受体（Fibroblast growth factor 21 receptor，FGF21R），胰高血糖素受体（Glucagon receptor，GCGR），和胰高血糖素样肽-1受体（Glucagon-like peptide-1 receptor，GLP-1R)的同类首创（FIC）的长效三特异性激动剂DR10624用于治疗代谢相关脂肪性肝病（MASLD）/代谢相关脂肪性肝炎（MASH）的II期临床试验已完成首例患者给药。 DR10624-202是一项随机、双盲、安慰剂对照II期临床研究，旨在评价3个不同剂量水平的 DR10624注射液在合并肝纤维化高风险的代谢相关脂肪性肝病受试者中的有效性、安全性。 DR10624-202研究将招募 96 名受试者。

Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia。 Hangzhou, Zhejiang, China, March 10, 2025, Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon receptor (GCGR), Glucagon-like peptide

Zhejiang Doer Biologics Completes Enrollment of the Phase 1b/2a Trial Evaluating DR10624 in Obese Subjects with Modest Hypertriglyceridemia.。 Hangzhou, Zhejiang, China, July3, 2024, Zhejiang Doer Biologics Co., Ltd. (“Doer Bio”), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announcesthat the company has completed the enrollment in the Phase 1b/2a trial evaluating DR10624in obese subjects with modest hypertriglyceridemia in New Zea